Korean Biotech at BIO USA 2026: Licensing Deals Over Product Launches

Korean drugmakers went to BIO USA 2026 to sell rights, not products. Across four days of partnering meetings, the delegation from Seoul was dominated by mid-cap developers and contract manufacturers whose business model rests on handing an asset to a larger partner before it ever reaches a patient — and the benchmark they were all measured against was Curacle’s 1.6 trillion won out-licensing of MT-103, the single largest deal any of them can point to.

Why the Partnering Calendar Matters More Than the Booth

For companies of this size, BIO’s value is almost entirely in the one-on-one meeting schedule. The Korean contingent that took part included G2GBIO, led by chief executive Lee Hee-yong; MedySapiens, whose chief executive Kang Sang-gu attended; Lotte Biologics, represented by technology development head Han Jae-jun; Kangstem Biotech, whose business development chief Eo Hae-gwan handled partnering; and Curacle, represented by business development executive Kim Jung-han. That roster is a fair cross-section of where Korean biotech actually competes: drug delivery platforms, AI-assisted genomic diagnostics, contract manufacturing capacity, cell therapy, and small-molecule assets aimed at licensing.

None of those categories wins on brand recognition in the United States. They win on whether a business development team can get in front of the right licensing counterpart during a compressed four-day window — which is why the delegation was built around BD heads rather than chief scientific officers.

The Curacle Effect

Curacle’s position in the conversation is instructive. A company with a completed 1.6 trillion won technology export has something most of its peers do not: proof that a Korean-originated asset can clear a global partner’s diligence. The obvious question the company now faces is what follows MT-103 — a successor asset has to carry the same story, because a single deal reads as luck until the second one arrives.

That is the structural problem for the whole cohort. Korean out-licensing has produced headline numbers, but those numbers are heavily front-loaded with milestone payments contingent on clinical progress that a licensor no longer controls. A trillion-won figure announced today may resolve into a fraction of that over a decade, and the partnering conversations at BIO are where companies try to line up the next one before the last one is fully banked.

Daewoong’s Pivot Toward Biosimilars

The most concrete strategic disclosure from the Korean side was Daewoong Pharmaceutical’s identification of biosimilars as its next growth engine, with Dupixent named as the first target. That is a notable shift for a company whose center of gravity has historically been elsewhere.

Daewoong is one of the older institutions in Korean pharmaceuticals. Its lineage runs back to a business established in 1942 under the Kawai Pharmaceutical name, formally incorporated in 1945 as Daehan Vitamin Chemical, renamed Daehan Vitamin Industrial in 1961, and acquired by Yoon Young-hwan in 1966 when the business was struggling. The Daewoong Pharmaceutical name itself dates only from 1978. The company is headquartered in Seoul.

Choosing Dupixent as a first biosimilar target is a high-difficulty entry point rather than a cautious one. Dupilumab is a blockbuster monoclonal antibody in atopic dermatitis and adjacent inflammatory indications, meaning the commercial prize is large and the field of would-be biosimilar developers is correspondingly crowded. Success depends less on the science of the molecule than on manufacturing cost, regulatory sequencing across markets, and whether Daewoong can secure distribution in territories where it has no existing commercial infrastructure. The company has not published a development timeline, so the practical question — whether this is a late-decade product or something further out — remains open.

What the Delegation’s Composition Reveals

Read together, the Korean presence at BIO USA 2026 describes an industry that has moved past the stage of hoping for interest and into the stage of managing a deal pipeline, but has not yet reached the stage of commercializing its own assets abroad. Lotte Biologics is selling capacity. G2GBIO and Kangstem are selling platforms and cell therapy programs. MedySapiens is selling analytical capability. Curacle is selling the credibility of a deal it already closed. Daewoong, uniquely, is describing a plan to build and sell a finished product itself.

The gap between those two postures — licensing out versus going to market — is the one worth tracking. Korea’s separate macroeconomic position drew its own attention this year, with the OECD releasing its 2026 economic survey of the country, but for the pharmaceutical sector specifically the measure of a successful BIO USA will not be visible for months. It shows up in signed term sheets, not in meeting counts.